Anmol Singh, MBBS1, Sahiljot Bhupal, MBBS2, Carol Singh, MBBS3, Ritika Dhruve, MBBS4, Vikash Kumar, MD5, Aalam Sohal, MD6, Juliana Yang, MD7 1Tristar Centennial Medical Center, Nashville, TN; 2Dayanand Medical College and Hospital, Chicago, IL; 3Dayanand Medical College and Hospital, Jalandhar, Punjab, India; 4University of Texas Southwestern Medical Center, Dallas, TX; 5Creighton University School of Medicine, Brooklyn, NY; 6Creighton University School of Medicine, Seattle, WA; 7University of Texas Medical Branch, Galveston, TX
Introduction: Aspirin is an anti-inflammatory drug used for primary prevention of cardiovascular events. Evidence suggests that low-dose aspirin use may decrease the incidence of colorectal. gastric and esophageal cancers. The current study examines the impact of long-term aspirin use on various gastrointestinal (GI) cancers.
Methods: We used the National Inpatient Sample 2016-2020 to identify adult patients ( >18 yrs.). Patients were stratified into two groups based on aspirin use. Patients with missing demographics or mortality were excluded. Data was collected on patient demographics, hospital characteristics, and comorbidities. The rates of GI cancers were compared between the 2 groups. The multivariate regression model was used to assess the relationship between aspirin and GI cancers.
Results: Out of 26,432,833 patients included in the analysis, 3,843,430 (14.54%) patients were long-term aspirin users. The majority of patients in the aspirin group were aged >65 years (66.7%), male (53.3%), white (72.1%) and had Medicare insurance (67.4%). Patients with a history of long-term aspirin use had lower rates of esophageal cancer (0.11% vs 0.15%, p< 0.001), gastric cancer (0.09% vs 0.15%,p< 0.001), liver cancer (0.21 vs 0.32%,p< 0.001), pancreatic cancer (0.33% vs 0.42%,p< 0.001), Gall bladder cancer (0.02 vs 0.03,p< 0.001), Bile duct cancer (0.07 vs 0.09,p< 0.001), small intestinal cancer (0.3 vs 0.046%,p< 0.001), and large intestinal cancer (0.06 vs 0.09,p< 0.001) (Figure 1). After adjusting for confounding factors, the relationship was significant for all the cancers, with the lowest odds noted for small intestinal cancer (aOR-0.48, 95% CI-0.41-0.56), followed by gastric cancer (aOR-0.49, 95% CI-0.45-0.53,p< 0.001), and esophageal cancer (aOR-0.53, 95% CI-0.49-0.57,p< 0.001). (Table 1).
Discussion: Our study highlights that long-term aspirin use was associated with a lower risk of development of various GI cancers, which might be secondary to the chemoprotective effects of aspirin. Further prospective studies are needed to confirm these results, which can have major implications for primary prevention of GI cancers.
Figure: Comparison of prevalence rates of various gastrointestinal cancer cancers among patients with and without aspirin use
Note: The table for this abstract can be viewed in the ePoster Gallery section of the ACG 2024 ePoster Site or in The American Journal of Gastroenterology's abstract supplement issue, both of which will be available starting October 27, 2024.
Disclosures:
Anmol Singh indicated no relevant financial relationships.
Sahiljot Bhupal indicated no relevant financial relationships.
Carol Singh indicated no relevant financial relationships.
Ritika Dhruve indicated no relevant financial relationships.
Vikash Kumar indicated no relevant financial relationships.
Aalam Sohal indicated no relevant financial relationships.
Juliana Yang indicated no relevant financial relationships.
Anmol Singh, MBBS1, Sahiljot Bhupal, MBBS2, Carol Singh, MBBS3, Ritika Dhruve, MBBS4, Vikash Kumar, MD5, Aalam Sohal, MD6, Juliana Yang, MD7. P1500 - Impact of Long-Term Aspirin Use on Various Gastrointestinal Cancers: Insights from National Inpatient Sample, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.
